SLXN (Silexion Therapeutics) Capex-to-Revenue : 0.00 (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Silexion Therapeutics Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Silexion Therapeutics's Capital Expenditure for the three months ended in Dec. 2024 was $0.00 Mil. Its Revenue for the three months ended in Dec. 2024 was $0.00 Mil.

GuruFocus do not calculate Capex-to-Revenue if the revenue is negative.

Silexion Therapeutics Capex-to-Revenue Historical Data

The historical data trend for Silexion Therapeutics's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Silexion Therapeutics Capex-to-Revenue Chart

Silexion Therapeutics Annual Data

Trend

Dec22

Dec23

Dec24

Capex-to-Revenue

Silexion Therapeutics Quarterly Data
	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Capex-to-Revenue	Get a 7-Day Free Trial				-	-	-	-	-

Competitive Comparison of Silexion Therapeutics's Capex-to-Revenue

For the Biotechnology subindustry, Silexion Therapeutics's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Silexion Therapeutics's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Silexion Therapeutics's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Silexion Therapeutics's Capex-to-Revenue falls into.

Save Embed

;

Save Embed

;

Silexion Therapeutics Capex-to-Revenue Calculation

Silexion Therapeutics's Capex-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (-0.022)	/	0
	=	N/A

Silexion Therapeutics's Capex-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (0)	/	0
	=	N/A

Silexion Therapeutics (NAS:SLXN) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.

Silexion Therapeutics Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Silexion Therapeutics's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Silexion Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Silexion Therapeutics Corp (NAS:SLXN) » Definitions » Capex-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

2 Ha mayan Street, Modi in-Maccabim-Reut, ISR, 7177871

Website

https://www.silexion.com

Silexion Therapeutics Corp is a developmental-stage company dedicated to the development of treatments for pancreatic cancer. The company is focused on enhancing its first-generation product (LODERTM ) to develop a newly formulated product to improve the clinical efficacy against pancreatic cancer.